Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399

BACKGROUND: CREBBP and EP300 mutations occur at a frequency of 15% and 13%, respectively, in small cell lung cancer (SCLC), and preclinical models demonstrated susceptibility to targeting with HDAC inhibitors. METHODS: Patients with treatment-naïve extensive-stage SCLC, ECOG ≤2 were enrolled and tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Gentzler, Ryan D, Villaruz, Liza C, Rhee, John C, Horton, Bethany, Mock, Joseph, Hanley, Michael, Kim, Kyeongmin, Rudek, Michelle A, Phelps, Mitch A, Carducci, Michael A, Piekarz, Richard, Park, Kwon-Sik, Bullock, Timothy N, Rudin, Charles M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628589/
https://www.ncbi.nlm.nih.gov/pubmed/37555284
http://dx.doi.org/10.1093/oncolo/oyad221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628589/
https://www.ncbi.nlm.nih.gov/pubmed/37555284
http://dx.doi.org/10.1093/oncolo/oyad221

Ejemplares similares